Doctor's Notes

Eczema Targeted Therapy and Hospital Visits: What a 157,966-Adult Claims Study Found

AI-generated illustration: Dr. Arsy Hydration Jar on Stone

Dr. Arsy Editorial Team · November 9, 2026

A retrospective US claims study examined whether starting a targeted atopic dermatitis therapy was associated with changes in hospitalizations, emergency-department visits and spending. The analysis included 157,966 adults; 9,320 received targeted therapy, almost all dupilumab.[4]

Observed changes after treatment initiation

Compared with changes in the non-targeted group, targeted therapy was associated with a 1.6-percentage-point decrease in the probability of hospitalization and a 1.7-point decrease in emergency visits. Total annual spending rose by about $24,901, driven by drug costs, while inpatient and outpatient spending fell. Patient out-of-pocket spending increased by an estimated $95.[4]

Why this is not a randomized cost-effectiveness trial

Difference-in-differences methods compare changes over time and can reduce some bias, but they assume the groups would otherwise have followed parallel trends. Insurance coverage, disease severity, clinician selection, comorbidities and healthcare access may still differ. All-cause hospital and emergency visits are also broader than eczema-specific events.

Association does not establish the best treatment for one person

Ninety-nine percent of the targeted group used dupilumab, so findings provide little direct evidence about other agents. Claims confirm billing events, not symptom scores, adherence or reasons for hospital visits. A higher pharmacy cost may or may not be justified by outcomes not captured in the analysis.

Questions for value-based decisions

  • What clinical and quality-of-life benefit is expected?
  • What monitoring and adverse-event risks apply?
  • What will insurance cover and what is the actual patient cost?
  • Are urgent visits decreasing for the right reasons?

Treatment value includes symptoms, safety, function, access and total healthcare use—not drug price or hospitalization counts alone.[9][12][13][14][17]

Where moisturizer fits

Dr. Arsy Moisturizer #003 provides cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in this study and should not be credited with the outcomes of systemic treatments, registries or health-service models.

Related evidence

Research and clinical references

  1. Patient treatment needs in atopic dermatitis: TREATgermany cohort.
  2. UP-TAINED minimal disease activity and quality of life.
  3. US atopic dermatitis prevalence estimates, 2019–2023.
  4. Targeted therapies, hospitalizations and emergency visits cohort.
  5. AD-REAL oral systemic treatment cohort.
  6. 48-week minimal disease activity real-world study.
  7. International TREAT Registry Taskforce core dataset.
  8. Treatment patterns and burden in moderate-to-severe atopic dermatitis.
  9. Real-world effectiveness of dupilumab: systematic review.
  10. Real-world upadacitinib effectiveness and safety.
  11. Baricitinib real-world atopic dermatitis study.
  12. Comparative effectiveness of systemic treatments network meta-analysis.
  13. Model-based meta-analysis of randomized eczema treatments.
  14. AAD adult systemic and phototherapy guideline.
  15. AAD adult topical therapy guideline.
  16. AAD pediatric management guideline.
  17. AAAAI/ACAAI atopic dermatitis guideline.
  18. Treat-to-target framework for atopic dermatitis.
  19. HOME core outcome set for atopic eczema.
  20. POEM validation and interpretability.
  21. RECAP long-term control instrument validation.
  22. Atopic dermatitis burden systematic review.
  23. Economic burden of atopic dermatitis in the United States.
  24. Quality of life measurement in atopic dermatitis.

Educational information only; not medical or financial advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes